AbbVie, Calico aim to advance cancer, neuro drugs through ten-year R&D pact; later extend deal
In a collaboration that could run as long as ten years, AbbVie Inc., and biotech start-up Calico Life Sciences LLC (diseases related to aging) aim to create a leading San Francisco R&D facility focused on age-related diseases--particularly neurodegeneration and cancer--to discover and accelerate development of new therapies.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com